SEC Form 4 · accession 0001104659-16-159821
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sol J Barer
Director
Period of report
Nov 29, 2016
Accepted (ET)
Nov 30, 2016 · 7:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 29, 2016 | D | 29,890 | — | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $19.25 | Nov 29, 2016 | D | 19,927 | D | May 1, 2014 | May 5, 2021 | Common Stock | 19,927 | 0 | D |
| Stock Option (Right to Buy)F2 | $17.64 | Nov 29, 2016 | D | 9,988 | D | Jun 1, 2014 | Jun 1, 2021 | Common Stock | 9,988 | 0 | D |
| Stock Option (Right to Buy)F2 | $15.00 | Nov 29, 2016 | D | 12,854 | D | Jun 5, 2015 | Jun 5, 2022 | Common Stock | 12,854 | 0 | D |
| Stock Option (Right to Buy)F2 | $64.73 | Nov 29, 2016 | D | 14,700 | D | Jun 26, 2014 | Jun 26, 2023 | Common Stock | 14,700 | 0 | D |
| Stock Option (Right to Buy)F2 | $32.55 | Nov 29, 2016 | D | 5,012 | D | Jun 26, 2015 | Jun 26, 2024 | Common Stock | 5,012 | 0 | D |
| Stock Option (Right to Buy)F2 | $17.98 | Nov 29, 2016 | D | 18,000 | D | Jun 26, 2016 | Jun 26, 2025 | Common Stock | 18,000 | 0 | D |
Explanation of responses
- F1Disposed of in exchange for 30,665 common shares of Novelion Therapeutics Inc. pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."
- F2Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor.